Pharmacokinetics quantifies how a drug is absorbed, distributed, metabolized, and excreted, and the raw output of that work is a concentration-time curve. A curve on its own is hard to act on. It becomes usable once it is reduced to parameters: a half-life a dosing interval can be built around, a clearance value that predicts accumulation, an exposure measure that can be compared across species and across studies. Two families of models perform that reduction, and they differ in how much structure they are willing to impose on the data.
Compartment Models Treat The Body As A Few Spaces
A compartment is a mathematical construct rather than an organ. Each one groups tissues whose drug distribution and elimination rates are assumed to be uniform, and that uniformity is what keeps the equations solvable with the sampling schedules a study can realistically support. The trade-off is easy to state and hard to escape: a tissue with intermediate perfusion has to be assigned to one side or the other, even when its behavior sits between them.
Choosing between one and two compartments is a judgement about the data as much as about the drug. Fitting statistics such as the Akaike information criterion can rank candidate structures, but a structure that cannot be justified physiologically, or that rests on a handful of points at the end of the curve, rarely earns its extra parameter.
One-Compartment And Two-Compartment Versions
In the one-compartment version the body is a single homogeneous space. After dosing, drug distributes instantly and evenly through it, and concentration falls only because elimination is removing drug. The model fits compounds that equilibrate quickly, including many intravenous doses where the distribution phase runs faster than the sampling schedule can resolve.
Interpretation rests on four parameters:
- Kel (Elimination Rate Constant): the rate at which the drug is eliminated from the body.
- t1/2 (Half-Life): the time required for the drug concentration to reduce by half.
- Vd (Volume of Distribution): an apparent volume in which the drug is distributed.
- CL (Clearance): the rate at which the drug is removed from the body.
The two-compartment version splits the body instead, into a central compartment of highly perfused organs such as heart, liver, and kidney, and a peripheral compartment of less perfused tissue such as fat and muscle. Drug enters the central space quickly and then equilibrates slowly with the peripheral one. The result is a curve that falls steeply at first, during distribution, and then more gently during elimination. The model is worth the extra parameter when that second phase is visible in the data rather than buried in assay noise.
- α (Distribution Rate Constant): the rate of drug transfer between the central and peripheral compartments.
- β (Elimination Rate Constant): the rate at which the drug is eliminated from the central compartment.
- V1 (Volume of Central Compartment) and V2 (Volume of Peripheral Compartment): the apparent volumes in each compartment.
What Compartment Models Gain And Give Up
The appeal is practical. A small parameter set is easy to explain to a project team, and the structure can be matched to the compound and to the question being asked, which is how distribution and elimination phases get described separately instead of being averaged into one number.
The limits are just as practical. Forcing the body into one or two well mixed spaces ignores how heterogeneous real tissue is, and because different laboratories may settle on different structures, parameters from two studies are not always directly comparable. A Vd from a two-compartment fit and a Vd from a one-compartment fit do not describe the same quantity, even when the labels look identical in a table.
Non-Compartment Models Analyze The Curve Itself
Non-compartment models, also called statistical moment theory or model-independent methods, assume no compartments at all. Parameters are calculated from the concentration-time data with statistical tools, and the trapezoidal rule does much of the arithmetic.
Trapezoid in calculation of non-compartment model
Two features define the approach. It keeps a global view of the whole curve rather than dividing the body into spaces, and it needs little beyond arithmetic on the observed points, so results can be produced without settling a structural argument first.
- MRT (Mean Residence Time): the average time a drug molecule stays in the body.
- AUC (Area Under the Curve): the total exposure of the body to the drug over time.
- CL (Clearance): the drug elimination rate, as in compartment models.
The strengths follow from that choice. Because nothing is assumed about compartments, the description stays close to the observed data, including for compounds with complex distribution and elimination patterns, and results compare more easily across studies, laboratories, and drugs. Any compound with linear pharmacokinetics can be analyzed this way.
The weaknesses follow from the same choice. Averaging over the whole curve means the individual phases of distribution and elimination are not separated, and the estimates can be sensitive to fluctuation in the terminal phase, where assay noise is largest and sampling intervals are often longest.
Reading The Two Together
The approaches answer different questions, and most programs end up needing both. Compartment models give a structured reading of how drug moves between spaces. Non-compartment models give a summary of exposure that travels well between studies, between species, and into a submission.
For Prisys Biotech, working in preclinical research, these models are part of routine interpretation: NHP Pharmacology studies supply the concentration-time data, ADME work explains where the shape of the curve comes from, and Pharmacodynamics (PD) endpoints supply the response side of the exposure-response question.
